NAUT:NASDAQNautilus Biotechnology, Inc. analysis
Data as of Oct 13, 2026 - not real-time
- Latest price
- $2.17
- Risk: high
- 9/10High risk
Summary
At $2.17, Nautilus Biotechnology, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 144.9%. Momentum indicators put RSI at 72.1 (overbought) with MACD reading bullish. Recent trading has carved out support near $0.8800 and resistance around $2.47.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 76.7% above the current quote.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 150.2%, a beta of 1.46 and a maximum drawdown of 78.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 76.7% above the current quote.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 150.2%, a beta of 1.46 and a maximum drawdown of 78.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top market events
- Nautilus Biotechnology Inc. stocks have been trading up by 15.14 percent amid heightened investor optimism from its...
- Detailed price information for Nautilus Biotechnology Inc NAUT-Q from The Globe and Mail including charting and trades.
Market outlook
Short term
< 1 yearNeutral
Model confidence1/101 out of 10
Key factors
- RSI at 72.1 signals overbought conditions
- Trading above the 200-day average of 2.07
- MACD momentum is positive
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- RSI at 72.1 signals overbought conditions
- Trading above the 200-day average of 2.07
- Analyst targets imply +76.7% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +76.7% versus the current price
- Negative return on equity of -36.2%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-2.9
ROE-36.21%
ROA-20.83%
Debt/Equity21.21
P/B Ratio2.1
Op. Cash Flow$-50235000
Free Cash Flow$-29418376
Industry P/E30.7
Technical analysis
TrendNeutral
RSI72.1
Support$0.88
Resistance$2.47
MA 20$1.40
MA 50$1.11
MA 200$2.07
MACDBullish
VolumeIncreasing
Fear & Greed Index94.27
Valuation
Target Price$3.83
Upside/Downside76.65%
GradeFair
TypeBlend
Risk assessment
Beta1.46
Volatility150.18%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.